Tisagenlecleucel

Novartis announces longer-term analyses from pivotal Kymriah® trials that showed durable responses are maintained in patients with advanced blood cancers

Retrieved on: 
星期六, 十二月 1, 2018
Medicine, Immune system disorders, Gene therapy, Breakthrough therapy, Novartis, Tisagenlecleucel, Cytokine release syndrome, Health

In these analyses, Kymriah continued to demonstrate strong efficacy with durable responses and maintained a consistent and well-characterized safety profile.

Key Points: 
  • In these analyses, Kymriah continued to demonstrate strong efficacy with durable responses and maintained a consistent and well-characterized safety profile.
  • Grade 3/4 cytokine release syndrome (CRS) as defined by the rigorous Penn Grading Scale occurred in 49% of patients.
  • Within eight weeks of infusion, 13% of patients experienced grade 3 neurological events, with no grade 4 events or cerebral edema1.
  • The patient's healthcare provider will do blood tests to check all of their blood cell counts after treatment with Kymriah.

Novartis wins esteemed Prix Galien Foundation Best Biotechnology Product Award for CAR-T cell therapy, Kymriah®

Retrieved on: 
星期一, 十月 29, 2018
Health, Biology, Medicine, Gene therapy, Cancer treatments, Biotechnology, Chimeric antigen receptor, Immune system, Tisagenlecleucel, Novartis, Therapy, Cancer

"It is a great honor to receive this prestigious award for Kymriah," said Liz Barrett, CEO, Novartis Oncology.

Key Points: 
  • "It is a great honor to receive this prestigious award for Kymriah," said Liz Barrett, CEO, Novartis Oncology.
  • Kymriah is an innovative immunocellular therapy, manufactured individually for each patient by reprogramming the patient's own immune system cells.
  • In 2012, Novartis and Penn entered into a global collaboration to further research, develop and commercialize CAR-T cell therapies, including Kymriah, for the investigational treatment of cancers.
  • The patient's healthcare provider will do blood tests to check all of their blood cell counts after treatment with Kymriah.

Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China

Retrieved on: 
星期四, 九月 27, 2018
Medicine, Health, Gene therapy, Cancer, Novartis, Cancer treatments, Tisagenlecleucel, Chimeric antigen receptor

(NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China.

Key Points: 
  • (NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah (tisagenlecleucel) in China.
  • CBMG will take the lead in the manufacturing process, and Novartis will lead distribution, regulatory and commercialization efforts in China.
  • "Together with Novartis, we hope to bring the first CAR-T cell therapy to patients in China.
  • Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases.

CAR-T Therapies Market, 2030 - Over 350 Product Candidates Being Developed for Various Oncological Indications

Retrieved on: 
星期四, 八月 30, 2018
Medicine, Health, Cancer treatments, Cancer, Gene therapy, Breakthrough therapy, Chimeric antigen receptor, Immune system, Axicabtagene ciloleucel, Therapy, Tisagenlecleucel

The "CAR-T Therapies Market, 2018-2030" report features an extensive study of the current market landscape and the future potential of CAR-T therapies.

Key Points: 
  • The "CAR-T Therapies Market, 2018-2030" report features an extensive study of the current market landscape and the future potential of CAR-T therapies.
  • In addition to the yearly chatter trends, the analysis highlights the most frequently talked about product candidates as well.
  • An overview of the various focus therapeutic areas of therapy developers, including an assessment of the opportunity offered by oncological and non-oncological disease indications.
  • A review of the key promotional strategies that have been adopted by the developers of the marketed CAR-T therapies, Kymriah and Yescarta.

Global CAR T Cell Therapy Market 2016-2026: The Most Hot Topic Discussed Among Oncologists Throughout the Globe

Retrieved on: 
星期四, 六月 14, 2018
Medicine, Health, Breakthrough therapy, Clinical medicine, Cancer treatments, Axicabtagene ciloleucel, Immunosuppressants, Gene therapy, Tocilizumab, Tisagenlecleucel, Therapy, Draft:Axicabtagene ciloleucel

The global CAR T cell therapy market is expected to expand at a CAGR of 5.96 % from 2017 to 2025.

Key Points: 
  • The global CAR T cell therapy market is expected to expand at a CAGR of 5.96 % from 2017 to 2025.
  • CAR T cell therapy is the most hot topic discussed among oncologist throughout the globe.
  • The FDA approved CAR T cell therapy are Tisagenleucel (Kymriah), Axicabtagene ciloleucel (Yescarta) and Tocilizumab (Actemra).
  • Global CAR T Cell Therapy Market, by Geography, 2017 (US$ Mn)
    Chapter 3.

Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma

Retrieved on: 
星期二, 五月 1, 2018
Medicine, Cancer, RTT, Lymphoma, Gene therapy, Clinical medicine, Non-Hodgkin lymphoma, T cells, Chimeric antigen receptor, Tisagenlecleucel, Hodgkin's lymphoma, Draft:Axicabtagene ciloleucel

Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma.

Key Points: 
  • Kymriah is not indicated for the treatment of patients with primary central nervous system lymphoma.
  • Kymriah is now the only CAR-T cell therapy to receive FDA approval for two distinct indications in non-Hodgkin lymphoma (NHL) and B-cell ALL.
  • Kymriah is an innovative immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient's own T cells.
  • The REMS program serves to inform and educate healthcare professionals about the risks that may be associated with Kymriah treatment.